Quince Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
QNCX Nasdaq 2836 quincetx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Quince Therapeutics, Inc.

Quince Therapeutics to Participate in September 2026 Investor Conferences - Sep 3rd, 2026 6:00 am
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update - Aug 14th, 2026 6:00 am
As Acasti Pharma Advances FDA Orphan-Designated GTX-102 Oral Mucosal Spray, New Report Maps 7MM Ataxia-Telangiectasia Treatment Landscape - Aug 14th, 2026 2:05 am
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board - Jun 30th, 2026 6:00 am
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - Jun 2nd, 2026 7:56 am
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - May 18th, 2026 8:21 am
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline - May 18th, 2026 7:26 am
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - May 18th, 2026 7:26 am
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure - Feb 2nd, 2026 5:19 am
Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls - Jan 30th, 2026 7:54 am